DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Published:2013-04-18 Issue:7 Volume:12 Page:1255-1265
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Li Dongwei,Poon Kirsten Achilles,Yu Shang-Fan,Dere Randall,Go MaryAnn,Lau Jeffrey,Zheng Bing,Elkins Kristi,Danilenko Dimitry,Kozak Katherine R.,Chan Pamela,Chuh Josefa,Shi Xiaoyan,Nazzal Denise,Fuh Franklin,McBride Jacqueline,Ramakrishnan Vanitha,de Tute Ruth,Rawstron Andy,Jack Andrew S.,Deng Rong,Chu Yu-Waye,Dornan David,Williams Marna,Ho William,Ebens Allen,Prabhu Saileta,Polson Andrew G.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Role of Target Expression in Treatment Efficacy of Antibody–Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review;Current Oncology Reports;2024-07-27

2. Surface-Available HER2 Levels Alone Are Not Indicative of Cell Response to HER2-Targeted Antibody–Drug Conjugate Therapies;Pharmaceutics;2024-06-02

3. A high-throughput lysosome trafficking assay guides ligand selection and elucidates differences in CD22-targeted nanodelivery;Science and Technology of Advanced Materials;2024-05-29

4. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression;CPT: Pharmacometrics & Systems Pharmacology;2024-03-26

5. Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma;Cancers;2024-02-18